Loss of Heterozygosity in BRCA Gene May Influence Survival in Breast and Ovarian Cancers

August 28, 2017 7:17 pm

Researchers in the Perelman School of Medicine at the University of Pennsylvania have found a relationship between the genetics of tumors with germline BRCA1/2mutations—and whether the tumor retains the normal copy of the BRCA1/2 gene—and risk for primary resistance … Read more

How PARP Inhibitors Might Prove Useful In More Than Just BRCA Cancers

August 2, 2017 7:56 pm

PARP inhibitor Lynparza (olaparib) has been embraced by oncologists treating women with BRCA-mutant ovarian cancer, and the AstraZeneca drug is also showing promise in breast cancers that harbor the same mutations. But scientists led by the University of Pennsylvania believe … Read more

PARP Inhibitor Active in BRCA Subgroups

March 14, 2017 5:52 pm

Patients with relapsed BRCA-mutated ovarian cancer had a similar progression-free survival (PFS) with the PARP inhibitor rucaparib (Rubraca) regardless of the type of mutation, according to subgroup analyses of a prospective, multicenter trial.

Results showed a median PFS of … Read more

The Unbearably Slow Adoption of Genetic Cancer Tests

July 12, 2016 5:29 pm

Over the past 20 years, Nazneen Rahman has identified a steady stream of genes that influence the risk of breast, ovarian, and childhood cancers—work that has earned her scientific, popular, and even royal acclaim. But her latest accomplishment, and one … Read more